(Reuters) — Hip and knee replacements, 2 of the fastest-growing U.S. medical procedures, are subject to huge – and apparently random – price variations within the same geographical areas, a new insurance industry study said yesterday.
Histogenics filed for an initial public offering, aiming to raise up to $65 million as it begins Phase III testing of its knee cartilage product NeoCart.
The regenerative medicine company plans to list its shares on the NASDAQ exchange under the symbol HSGX.
A meta-analysis of new generations of knee and hip replacement devices could bode ill for orthopedics makers.
In a study published this week in The BMJ, researchers warned that many innovative new implants may actually have worse durability and safety profiles than their predecessors.
MASSDEVICE ON CALL — The U.S. hip and knee replacement market has gotten a recent boost as patients are opting to undergo the procedures earlier, the Telegraph reported.
The trends has turned the devices into something of a consumer good, industry analysts said.
Total knee arthroplasty patients are trending younger and heavier, while Medicare and Medicaid recipients who undergo total hip arthroplasties run a higher risk of needing revision surgeries, according to a pair of recent studies.
Joint pain cut years from Jonathan Bender’s professional basketball career, but it also gave him a future.
The former NBA player, who made the jump from high school directly to the pros in 1999, spent 7 injury-plagued seasons with the Indiana Pacers before bowing out in 2006 (Bender returned in 2010 for a half season with the New York Knicks).